BlueLight Therapeutics uses a proprietary structure-based platform to discover small molecules against difficult-to-drug targets.
BlueLight Therapeutics uses a proprietary structure-based platform to discover small molecules against difficult-to-drug targets.
BlueLight Therapeutics leverages a proprietary, structure-driven platform to develop novel therapeutic molecules against challenging, high-value drug targets. The company has a passionate and experienced team with unique expertise on developing structural assays across a broad range of target classes.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 20, 2013 | Grant | $100K | 1 |
![]() |
— | Detail |
Mar 18, 2013 | Grant | $1.10M | 1 |
![]() |
— | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Oct 13, 2011
![]() |
Series Unknown | $3M | Internet | — |
Jun 30, 2010
![]() |
Series A | $1.30M | Analytics | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Grant |